DC Biosciences provides pharmaceutical and biotechnology companies with novel approaches and proteomic services to accelerate the development of safer drugs. We are well-positioned to apply our extensive knowledge and experience across a broad range of proteomic disciplines including protein profiling, quantitative proteomics, protein post-translational modifications, and affinity proteomics; and also to deliver solutions in key areas of drug discovery and development.
“The whole process is very flexible and I particularly liked the possibility to work out the entire experimental setup and protocols with you beforehand.”
Nikita Gamper, University of Leeds (November 2020)
“Very knowledgeable and responsive, an excellent collaboration.”
Sarah Seiler Hogan, Unither Pharmaceuticals (November 2020)
The ADAPTED (Alzheimer’s Disease Apolipoprotein Pathology for Treatment Elucidation and Development) project was a major new initiative to investigate an area of Alzheimer’s Disease (AD) research that has previously received little attention. The project aimed to improve understanding of the function of the APOE gene. APOE is well known as a risk factor for developing […]
Latest News from DC Biosciences: The team at DC Biosciences is excited about bringing new ideas and an improved focus as the world moves forward to an easier and more productive time. Our aim is to provide a more dynamic and diverse proteomic service enabling us to provide the best match for your unique research […]
Our commitment to pursue the most pioneering, leading-edge proteomic technologies has driven us to add de novo Protein and Antibody Sequencing to our service provision. “This year we will focus on ensuring a seamless results-driven service and apply our extensive knowledge and experience across a broad range of pioneering proteomic disciplines to provide our customers with […]
